Premium
Radiotherapy for low‐grade gastric marginal zone lymphoma: a retrospective study
Author(s) -
Lin M.L.,
Wirth A.,
Chao M.,
Milner A. D.,
DiIulio J.,
MacManus M.,
Seymour J. F.
Publication year - 2007
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/j.1445-5994.2006.01291.x
Subject(s) - medicine , radiation therapy , stomach , retrospective cohort study , toxicity , surgery , gastroenterology , lymphoma , cancer , chemotherapy
Background: We evaluated the efficacy and toxicity of radiotherapy (RT) in patients with low‐grade gastric marginal zone lymphoma. Methods: A retrospective review of consecutive cases of gastric marginal zone lymphoma treated by radical RT at the Peter MacCallum Cancer Centre and Radiation Oncology Victoria between January 1980 and September 2003 was carried out. Results: Eighteen patients (11 men and 7 women) were identified. The median age at commencement of RT was 65 years (range 42–84 years). Prior treatment included Helicobacter pylori eradication in 12 patients, chemotherapy in 7 and surgery in 2, whereas 2 patients had no prior therapy. The median time to progression after commencement of last treatment before RT was 4.8 months (range 0–129.4 months). The radiation fields included the stomach plus perigastric and coeliac nodes in 15 patients (83%), stomach plus spleen in 2 patients (11%) and stomach plus para‐aortic nodes in 1 patient (6%). The median RT dose was 30 Gy (range 30–36 Gy) in a median 20 fractions (range 17–24 fractions). One patient required treatment interruption for acute toxicity. A complete response on post‐RT biopsies was achieved in 17 of 18 patients (94%). With a median follow up of 4.5 years after RT, 3 of these 17 patients (18%) have had a recurrence. At the last follow up, 11 patients were alive in continuous complete histological remission. No late renal toxicity was identified. Conclusion: Radiotherapy is an effective, well‐tolerated treatment for patients with low‐grade gastric marginal zone lymphoma, including those who have had prior therapy.